ABP-601
- Generic Name
- ABP-601
China Medical System Gains Exclusive Rights to Gout Drug ABP-671
• China Medical System secured exclusive rights to commercialize Atom Therapeutics' ABP-671 in Mainland China, Hong Kong, and Macao for gout and hyperuricemia treatment.
• ABP-671, a novel URAT1 inhibitor, is currently in Phase 2b/3 clinical trials and has demonstrated favorable efficacy and safety profiles in earlier studies.
• The agreement spans ten years post-market approval, with a potential ten-year renewal, aligning with CMS's strategic expansion in rheumatology and related fields.
• With a high prevalence of hyperuricemia and gout in China, ABP-671 addresses an urgent need for safer and more effective uric acid-lowering treatments.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath